CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
varenicline +2 moredrug
Likely dose
varenicline 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00580853
NCT00580853Phase 2Completed
CompareCT.gov

The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior

Yale University·interventional·Posted Dec 27, 2007·Updated Feb 8, 2018

In Brief

A Phase 2 clinical trial evaluating varenicline, bupropion, and 1 other intervention for Smoking Lapse Behavior. Completed, enrolled 62 participants across 1 site.

Detailed Summary

The purpose of this study is to examine how smoking cessation medications (varenicline, bupropion) affect the ability to resist smoking and also subsequent ad-lib smoking in non-treatment seeking daily smokers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Lapse Behavior
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 27, 2007
Enrollment StartApr 1, 2007
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.5 yearsPosted 18.5 years ago

Interventions

vareniclinedrug

2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).

bupropiondrug

300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).

Placebodrug

Placebo